356 related articles for article (PubMed ID: 36571557)
21. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
Ashoor IF; Al-Akash S; Kizilbash S; Moudgil A; Puliyanda D; Ranabothu S; Shi Y; Dharnidharka V
Pediatr Transplant; 2024 May; 28(3):e14743. PubMed ID: 38566336
[TBL] [Abstract][Full Text] [Related]
22. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
[TBL] [Abstract][Full Text] [Related]
23. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations.
Courville EL; Yohe S; Chou D; Nardi V; Lazaryan A; Thakral B; Nelson AC; Ferry JA; Sohani AR
Mod Pathol; 2016 Oct; 29(10):1200-11. PubMed ID: 27443517
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
25. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
Offor UT; Bacon CM; Roberts J; Powell J; Brodlie M; Wood K; Windebank KP; Flett J; Hewitt T; Rand V; Hasan A; Parry G; Gennery AR; Reinhardt Z; Bomken S
J Heart Lung Transplant; 2021 Jan; 40(1):24-32. PubMed ID: 33339556
[TBL] [Abstract][Full Text] [Related]
26. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Kinch A; Sundström C; Tufveson G; Glimelius I
Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
[TBL] [Abstract][Full Text] [Related]
27. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
28. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
Baldanti F; Rognoni V; Cascina A; Oggionni T; Tinelli C; Meloni F
Virol J; 2011 Sep; 8():421. PubMed ID: 21892950
[TBL] [Abstract][Full Text] [Related]
29. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
Chang YC; Young RR; Mavis AM; Chambers ET; Kirmani S; Kelly MS; Kalu IC; Smith MJ; Lugo DJ
PLoS One; 2022; 17(10):e0269766. PubMed ID: 36256635
[TBL] [Abstract][Full Text] [Related]
31. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.
Luskin MR; Heil DS; Tan KS; Choi S; Stadtmauer EA; Schuster SJ; Porter DL; Vonderheide RH; Bagg A; Heitjan DF; Tsai DE; Reshef R
Am J Transplant; 2015 Oct; 15(10):2665-73. PubMed ID: 25988622
[TBL] [Abstract][Full Text] [Related]
32. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
[TBL] [Abstract][Full Text] [Related]
33. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
34. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
35. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
36. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
37. Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes.
Stubbins RJ; Mabilangan C; Rojas-Vasquez M; Lai RL; Zhu J; Preiksaitis JP; Peters AC
Leuk Lymphoma; 2020 Dec; 61(14):3319-3330. PubMed ID: 32878528
[TBL] [Abstract][Full Text] [Related]
38. Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Yeung S; Stephens D; Punnett AS; Barton M; Allen UD
Transplantation; 2019 Nov; 103(11):e369-e374. PubMed ID: 31385930
[TBL] [Abstract][Full Text] [Related]
39. Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphoma.
Kim JH; Cho H; Sung H; Jung AR; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Park CS; Yoon DH; Suh C
Sci Rep; 2021 Feb; 11(1):2880. PubMed ID: 33536508
[TBL] [Abstract][Full Text] [Related]
40. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]